Overview

• A class action lawsuit has been filed against SCYNEXIS, Inc. alleging the company made false or misleading statements and omitted material adverse information regarding its business, operations, and prospects.
• The lawsuit alleges that the equipment used to manufacture ibrexafungerp, a drug developed by SCYNEXIS, was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination.
• The lawsuit also alleges that SCYNEXIS did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP).
• Due to the substantial risk of cross-contamination, SCYNEXIS was reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies, according to the lawsuit.
• Investors who bought SCYNEXIS shares between March 31, 2023 and September 22, 2023, and suffered a significant loss on that investment, are being encouraged to discuss their legal rights.